Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.31 |
| ▸ | YWHAG | P61981 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20887111 | 0.88 | MEN1 (0.34) | MEN1USP2POLBHSP90AA1HSP90AB1 | |
| SCHEMBL22651668 | 0.86 | HSD17B10 (0.31) | MEN1USP2POLBHSP90AA1HSP90AB1 | |
| SCHEMBL22193121 | 0.84 | HSD17B10 (0.47) | MEN1USP2POLBHSP90AA1HSP90AB1 | |
| SCHEMBL23425343 | 0.82 | MEN1 (0.37) | MEN1USP2POLBHSP90AA1HSP90AB1 | |
| SCHEMBL12515067 | 0.77 | CA1 (0.33) | MEN1USP2POLBHSP90AA1HSP90AB1 | |
| SCHEMBL21319383 | 0.76 | F2 (0.32) | — | |
| SCHEMBL23683711 | 0.74 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL19117713 | 0.73 | CYP2C9 (0.34) | MEN1USP2POLBHSP90AA1HSP90AB1 | |
| SCHEMBL13657235 | 0.69 | SOS1 (0.42) | MEN1USP2POLBHSP90AA1HSP90AB1 | |
| SCHEMBL28787828 | 0.65 | HSD17B10 (0.48) | MEN1USP2POLBHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157198-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157198-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | MEN1 951/4885USP2 2877/4885POLB 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.